Tristan T Sands1, Martina Balestri2, Giulia Bellini3, Sarah B Mulkey4, Olivier Danhaive5, Eliza Hayes Bakken5, Maurizio Taglialatela6, Michael S Oldham1, Federico Vigevano2, Gregory L Holmes7, Maria Roberta Cilio1. 1. Department of Neurology, University of California San Francisco, San Francisco, California, U.S.A. 2. Department of Neurology, Bambino Gesú Children's Hospital and Research Institute, Rome, Italy. 3. Department of Experimental Medicine, Second University of Naples, Naples, Italy. 4. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, U.S.A. 5. Department of Pediatrics, University of California San Francisco, San Francisco, California, U.S.A. 6. Department of Health Science, University of Molise, Campobasso, Italy. 7. Department of Neurological Sciences, University of Vermont, College of Medicine, Burlington, Vermont, U.S.A.
Abstract
OBJECTIVE: To evaluate treatment responses in benign familial neonatal epilepsy (BFNE). METHODS: We recruited patients with BFNE through a multicenter international collaboration and reviewed electroclinical and genetic details, and treatment response. All patients were tested at minimum for mutations/deletions in the KCNQ2, KCNQ3, and SCN2A genes. RESULTS: Nineteen patients were included in this study. A family history of neonatal seizures was positive in 16 patients, and one additional patient had a family history of infantile seizures. Mutations or deletions of KCNQ2 were found in 14, and of KCNQ3 in 2, of the 19 patients. In all patients, seizures began at 2-5 days of life and occurred multiple times per day. Four patients developed status epilepticus. Seizures were focal, alternating between hemispheres, and characterized by asymmetric tonic posturing associated with apnea and desaturation, followed by unilateral or bilateral asynchronous clonic jerking. Twelve of 19 patients were treated with multiple medications prior to seizure cessation. Seventeen of (88%) 19 patients were seizure-free within hours of receiving oral carbamazepine (CBZ) or oxcarbazepine (OXC). Earlier initiation of CBZ was associated with shorter hospitalization (p < 0.01). No side effects of CBZ were reported. All patients had normal development and remain seizure-free at a mean follow-up period of 7.8 years (6 months-16 years). SIGNIFICANCE: This study provides evidence that CBZ is safe and rapidly effective in neonates with BFNE, even in status epilepticus. We propose that CBZ should be the drug of choice in benign familial neonatal seizures. Wiley Periodicals, Inc.
OBJECTIVE: To evaluate treatment responses in benign familial neonatal epilepsy (BFNE). METHODS: We recruited patients with BFNE through a multicenter international collaboration and reviewed electroclinical and genetic details, and treatment response. All patients were tested at minimum for mutations/deletions in the KCNQ2, KCNQ3, and SCN2A genes. RESULTS: Nineteen patients were included in this study. A family history of neonatal seizures was positive in 16 patients, and one additional patient had a family history of infantile seizures. Mutations or deletions of KCNQ2 were found in 14, and of KCNQ3 in 2, of the 19 patients. In all patients, seizures began at 2-5 days of life and occurred multiple times per day. Four patients developed status epilepticus. Seizures were focal, alternating between hemispheres, and characterized by asymmetric tonic posturing associated with apnea and desaturation, followed by unilateral or bilateral asynchronous clonic jerking. Twelve of 19 patients were treated with multiple medications prior to seizure cessation. Seventeen of (88%) 19 patients were seizure-free within hours of receiving oral carbamazepine (CBZ) or oxcarbazepine (OXC). Earlier initiation of CBZ was associated with shorter hospitalization (p < 0.01). No side effects of CBZ were reported. All patients had normal development and remain seizure-free at a mean follow-up period of 7.8 years (6 months-16 years). SIGNIFICANCE: This study provides evidence that CBZ is safe and rapidly effective in neonates with BFNE, even in status epilepticus. We propose that CBZ should be the drug of choice in benign familial neonatal seizures. Wiley Periodicals, Inc.
Authors: Renée A Shellhaas; Courtney J Wusthoff; Tammy N Tsuchida; Hannah C Glass; Catherine J Chu; Shavonne L Massey; Janet S Soul; Natrujee Wiwattanadittakun; Nicholas S Abend; Maria Roberta Cilio Journal: Neurology Date: 2017-07-21 Impact factor: 9.910
Authors: Rebecca Truty; Nila Patil; Raman Sankar; Joseph Sullivan; John Millichap; Gemma Carvill; Ali Entezam; Edward D Esplin; Amy Fuller; Michelle Hogue; Britt Johnson; Amirah Khouzam; Yuya Kobayashi; Rachel Lewis; Keith Nykamp; Darlene Riethmaier; Jody Westbrook; Michelle Zeman; Robert L Nussbaum; Swaroop Aradhya Journal: Epilepsia Open Date: 2019-07-01
Authors: Jasmine Maghera; Jingru Li; Shawn M Lamothe; Marvin Braun; Juan P Appendino; P Y Billie Au; Harley T Kurata Journal: Epilepsia Open Date: 2020-10-17
Authors: Domenico Umberto De Rose; Sara Cairoli; Marco Dionisi; Alessandra Santisi; Luca Massenzi; Bianca Maria Goffredo; Carlo Dionisi-Vici; Andrea Dotta; Cinzia Auriti Journal: Int J Mol Sci Date: 2020-08-17 Impact factor: 5.923